Clinical Trials
BlAsp 30 plus pioglitazone provides an effective treatment option for type 2 diabetes
Published in Obesity and Diabetes Week, December 12th, 2005
"Few large randomized controlled trials have assessed the value of adding insulin to an oral antidiabetic drug regimen. This trial compared the efficacy and safety of biphasic insulin aspart 30/70 (BIAsp 30) plus pioglitazone (n=93), glibenclamide (glyburide) plus pioglitazone (n 91), or BIAsp 30 monotherapy (n=97)," scientists in Israel report.
I. Raz and colleagues working with the Hadassah Hebrew University Hospital explained, "This 18-week, multinational, multicenter, randomized, open-label, parallel-group trial involved 281 patients with type 2 diabetes (60%...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Diabetes Pathology
MAPK-3 activates PEPCK gene transcription and increases gluconeogenesis in rat model - Disease Associations
Sleep apnea is linked to altered glucose metabolism and may lead to type 2 diabetes - Fitness & Wellness
Youth participating in weight reduction program kept weight loss at least 4 years - Obesity Epidemiology
Gly482Ser polymorphism in PPARGC1 links obese variances observed in metabolic syndrome - Obesity Pathogenesis
Raised SCD1 expression in skeletal muscle of obese adds to abnormal fatty acid partitioning - Apoptosis
Adipocyte death defines macrophage localization and function in the WAT of obese mice - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
